Recent papers have again highlighted the consistently high use of neuroleptic agents among people with a learning disability, despite the lack of good evidence to support their role in this population for behaviour management and despite the risks of such medication. Evidence suggests, however, that prescribing habits have remained relatively unchanged; the reasons for this are poorly understood. Given the lack of understanding about the factors contributing to such drug use, and the possibility that use of neuroleptics will increase as people with learning disabilities move into the community, there seems a clear need for clinical guidelines to cover the prescribing and monitoring of neuroleptics within this group. Such guidelines should also ensure that reviews, using reliable measures of treatment efficacy, are carried out regularly.
For the sake of clarity the tenn leaming disability is used throughout this paper and replaces the various other terms (for example, mental handicap, mental retardation, and developmental disability) used to describe the same client population in some of the papers mentioned.
Behavioural medication and learning disability
Several recent studies in Britain and abroad have again attested to the widespread use of psychotropic medication in people with learning disabilities.'4 It is estimated that most people with a leaming disability receive one or more drugs to control behaviour, including stimulants, anticonvulsants, antidepressants, major tranquillisers, and anxiolytics.5 Overall, those most commonly used in managing behaviour are neuroleptics. In a recent review of 168 people with leaming disabilities living in hospital, 49% were receiving neuroleptic medication. ' Standard psychopharmacology text books assert that the clearest indication for the use of neuroleptic medication is to treat psychiatric disorders, where the symptoms they aim at decreasing are causing suffering and disability for the client.6 Estimates for serious psychiatric disorders in people with leaming disabilities range from 8% to 15%.' One recent American survey of over 40 000 people with leaming disabilities living in hospital or in the community noted a prevalence for psychoses of 6-68% in people under 22 years of age and of 5-69% in people aged 22 years and over. 8 The incidence of shizophrenia alone has been estimated as 3-4% among hospital residents. ' Although there is a consensus that the prevalence of psychiatric illness in people with leaming disabilities is greater than that in the general population, the true rate is notoriously difficult to verify. This is partly because people with severe to profound disability are unlikely to be able to give adequate or reliable self reports, and partly because most studies have concentrated on hospital populations, which are by definition unrepresentative of the client group as a whole. Studies on this topic have also been criticised for using vague 184 BMJ VOLUME 307 
the policy of the medical administration at the institution to reduce or eliminate psychotropic drugs whenever possible. However an investigation at the same institution ten years earlier when the population was 50% higher showed exactly the same frequency (49%) of psychotropic drug use." 3 Similarly, in a British study nursing staff were aware of the importance of reviewing the use of psychotropic drugs, had an increased awareness of the potential risks associated with them, especially in patients with a learning disability, and had received training wherein they were encouraged to "eschew" such medication. Although a reduction in dosage was noted between the time of the study and four years previously, 47 of the 243 patients (24%) found to be taking neuroleptic drugs had not been receiving these drugs four years before and had been started on them during the interim. Of these 47 patients, 27 were diagnosed as having a behaviour disorder, which, as the authors point out, is "not a category which automatically lends itself to the prescription of anti-psychotic medication." 26 Finally, it has also been suggested that prescribing factors in institutions may be influenced by nonmedical factors such as the availability of a physician or psychiatrist. Although a high correlation between neuroleptic drug dosage and the availability of a physician may reflect physicians' tendency to quickly administer drugs, Linaker To illustrate this, imagine a hospital with 100 clients, 60 of whom are receiving neuroleptic drugs. After two years of resettlement 50 of the most able clients are living in the community; these include the 40 who were not taking neuroleptics and 10 who were. A survey of prevalence at this point would find that 100% of hospital residents were taking neuroleptics, compared to 20% of those in the community, yet the true prescribing rate has remained unchanged. Interestingly, one group of British researchers who followed the community move of 81 people with a learning disability in the west midlands found that "of the 64 people for whom full information was obtained, 24 (37.5%) were receiving anti-psychotic drugs two years before discharge, 25 (39%) at discharge, and 25 (39%) after living in the community for at least six months."33 This finding would certainly suggest that neuroleptic drug use does not necessarily decrease solely because people no longer live in institutions.
Another possible explanation for high rates of neuroleptic use in the community is that neuroleptics in this population are given for reasons in addition to those usually used in hospitals, possibly because less maladaptive behaviours are considered more serious in the community. Thus, behaviours that may at one time have been tolerated as the norm or not seen as problematic in institutions become more conspicuous in community settings. One study found that use of major tranquillisers was significantly related to hyperactivity and withdrawal among community based residents and to violent or destructive behaviour, and level of clients' physical development among institution based residents. 24 The general practitioner's increasing role As more people with learning disabilities move into the community, more general practitioners are going to become involved in meeting their health needs, in keeping with the philosophy of community care. A major reason for consultations is likely to be the pharmacological management of maladaptive behaviours. General practitioners are unlikely to have specialised in either learning disability or behavioural pharmacology. 16 disabilities, a consensus seems to be emerging on the need for clinical protocols to control for the prescribing, monitoring, and reviewing of behavioural drugs in learning disability. Researchers contend that these drugs ought to be given as part of an individualised habilitation plan and "according to guidelines which ensure that they are carefully monitored for both their intended and unintended effects."24 Others -have suggested that the construction of a well conceived drug evaluation strategy will not only improve medical practice but also increase adaptive behaviours, increase the likelihood of successful community placement, and decrease the risk of serious side effects.36 Similar sentiments have been echoed elsewhere.'6 17 37 The effectiveness of such guidelines in decreasing the use of pharmacological treatment in this population has already been shown.3839 Reductions gained after the introduction of approaches requiring systematic monitoring and evaluation have also been maintained after eight years of follow up. 40 
Conclusion
As increasing numbers of people with a leaming disability move into the community, there is little to suggest that those already taking neuroleptics will stop, some evidence to suggest that those not taking them may get them, and considerable evidence to suggest that most of those receiving them should not be doing so. Attempts to explain prescribing levels in terms of non-medical factors have been conflicting, and there is a poverty of good longitudinal research to explain many of the findings made to date.
Intuitively appealing interventions such as increased staffing levels, increased staff education, greater recreational activities, or better housing may not be the panaceas we might all like them to be. In addition, the possibility that use of neuroleptic drugs may become even more commonplace in the community because of the greater cost of altemative management strategies, the financial pressures of fundholding general practitioners and carers, and the possible utilisation of neuroleptics for a wider range of behaviours warrants cautious attention and future research.
In the absence of adequate knowledge about those variables controlling neuroleptic use, there seems a clear need for guidelines to ensure that adequate riskbenefit analyses are carried out at assessment and that medication, if given, is properly monitored, with regular reviews built into the process. Such reviews ought to include reliable measures of not only the behaviour for which the drug was given but also of those behaviours which the drug is known to affect.
